secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001933414-25-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Mineralys' lorundrostat Phase 2 trial in obstructive sleep apnea with hypertension
--------------------------------------------------------------------------------

- FDA cleared IND for Phase 2 trial of lorundrostat in moderate-to-severe OSA with hypertension.
- Trial to evaluate effect on apnea-hypopnea frequency & nocturnal hypertension; initiation expected Q1 2025.
- Approximately 40 subjects, placebo-controlled crossover design at up to 40 sites.
- Cash, cash equivalents & investments expected to fund operations through Q1 2026.
- This is the third targeted indication for lorundrostat, following hypertension and CKD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000002/0001933414-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000002/mlys-20250108.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer